Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024

Dogwood Therapeutics, Inc.

2024-Q2 EPS reported -$0.11

Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.
Cash $3.0M at June 30, 2024; expects runway into Q1 2025 after $1.7M public offering.
Enrollment completed in Long-COVID Phase 2a (valacyclovir/celecoxib vs placebo); top-line data October 2024.
R&D expense fell to $0.3M from $0.6M; G&A fell to $0.7M from $0.9M, both YoY.
Blinded safety analysis shows no serious adverse events; study drug well tolerated to date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.